CINC: CinCor Pharma, Inc. - Summary | Jitta

CinCor Pharma, Inc.

NASDAQ:CINC

Notice
Stock data is unavailable or the company’s delisted.
Price
$29.06
Loss Chance
58.4%
0.48JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (6)
Financial Strength (27)
Return to Shareholders (0)
Competitive Advantage (1)
Jitta Signs
SG&A to SalesDecreasing Every Year
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 97.69% in the last quarter (yoy)
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
0.48
100.00%
2.24
314.31%
2.24
314.31%
COMPANY DESCRIPTION
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc.